AdaptHealth (NASDAQ:AHCO) Sets New 1-Year Low – Should You Sell?

AdaptHealth Corp. (NASDAQ:AHCO)’s share price reached a new 52-week low during trading on Monday . The stock traded as low as $5.39 and last traded at $5.3150, with a volume of 354138 shares traded. The stock had previously closed at $5.69.

Key Headlines Impacting AdaptHealth

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: Director Kenneth Samet purchased 23,500 shares at an average price of $6.38, investing approximately $149,930 and nearly doubling his direct ownership. The transaction may be viewed as a sign of management confidence after the stock’s sharp decline. Kenneth Samet Buys 23,500 Shares of AdaptHealth Stock
• Positive Sentiment: AdaptHealth’s second-quarter earnings call and follow-up analyst coverage keep attention focused on management’s operating outlook and responses to questions about growth, profitability and execution. The company maintains broad analyst support, with seven Buy ratings and a reported consensus rating of Moderate Buy. AdaptHealth Q2 2026 Earnings Call Transcript
• Neutral Sentiment: A report showing zero reported short interest and zero days to cover provides no meaningful evidence of short-covering demand; the figures may reflect incomplete or erroneous data rather than a genuine market-positioning change.
• Negative Sentiment: Analysts have sharply reduced their valuation targets: Truist cut its target from $14 to $9, while UBS lowered its target from $14 to $10. Although both retained Buy ratings, the revisions signal greater caution about AdaptHealth’s near-term earnings outlook. The average target remains approximately $10.29, implying potential upside but also highlighting the gap between expectations and the current valuation. AdaptHealth Analyst Ratings

Wall Street Analysts Forecast Growth

AHCO has been the subject of a number of analyst reports. Canaccord Genuity Group set a $10.00 price target on AdaptHealth in a research report on Wednesday, August 5th. Wall Street Zen lowered AdaptHealth from a “buy” rating to a “hold” rating in a report on Saturday. Robert W. Baird set a $10.00 price objective on AdaptHealth in a research note on Wednesday, August 5th. Truist Financial reduced their target price on AdaptHealth from $14.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of AdaptHealth in a research report on Friday, May 22nd. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.29.

AdaptHealth Price Performance

The company has a market capitalization of $767.92 million, a P/E ratio of -3.30, a PEG ratio of 0.27 and a beta of 1.47. The stock’s fifty day simple moving average is $9.79 and its 200-day simple moving average is $10.48. The company has a debt-to-equity ratio of 1.37, a current ratio of 1.12 and a quick ratio of 0.98.

Insider Activity

In other AdaptHealth news, insider Russell E. Schuster III sold 11,275 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $10.06, for a total value of $113,426.50. Following the sale, the insider owned 136,538 shares of the company’s stock, valued at $1,373,572.28. This trade represents a 7.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kenneth A. Samet purchased 23,500 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was acquired at an average cost of $6.38 per share, for a total transaction of $149,930.00. Following the completion of the transaction, the director owned 48,569 shares in the company, valued at approximately $309,870.22. This trade represents a 93.74% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.95% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AdaptHealth

Several hedge funds and other institutional investors have recently modified their holdings of AHCO. Handelsbanken Fonder AB bought a new position in AdaptHealth during the second quarter worth $226,000. Empowered Funds LLC grew its position in AdaptHealth by 1.4% in the 1st quarter. Empowered Funds LLC now owns 622,904 shares of the company’s stock worth $7,413,000 after purchasing an additional 8,602 shares during the last quarter. Quantinno Capital Management LP increased its holdings in shares of AdaptHealth by 140.0% during the 1st quarter. Quantinno Capital Management LP now owns 109,694 shares of the company’s stock worth $1,305,000 after purchasing an additional 63,992 shares during the period. Lazard Asset Management LLC increased its holdings in shares of AdaptHealth by 35.0% during the 1st quarter. Lazard Asset Management LLC now owns 1,669,454 shares of the company’s stock worth $19,867,000 after purchasing an additional 432,664 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of AdaptHealth by 10.1% during the first quarter. Renaissance Technologies LLC now owns 228,373 shares of the company’s stock valued at $2,718,000 after buying an additional 21,000 shares during the last quarter. Institutional investors and hedge funds own 82.67% of the company’s stock.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.